The effect of a standardized polyherbal formulation for endometriosis-associated pain: A randomized double-blind placebo-controlled clinical trial

Elham Akhtari, Fataneh Hashem-Dabaghian, A H Jamshidi, Akram Fallah, Majid Dadmehr
In: Journal of Medicinal Plants · 2024 · vol. 23(91) , pp. 75–87 · doi:10.61186/jmp.23.91.75 · W4410361234
RCT OA: hybrid CC0
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This randomized, double-blind, placebo-controlled trial found that the polyherbal formulation Proscur significantly reduced endometriosis-associated pain and CA-125 levels with minimal side effects in young women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background: Dysmenorrhea, dyspareunia and endometriosis-associated pain are considered the main complications in young women with endometriosis.Proscur capsule contains several traditional herbal medicines that have shown anti-inflammatory, antioxidant, anti-androgenic, anti-estrogenic, pelvic pain reducing and analgesic effects in previous pre-clinical and clinical studies.Objective: This study aimed to investigate the clinical efficacy and safety of a standardized polyherbal formulation (proscur) for endometriosis-associated pain in young women with endometriosis.Methods: This study was a single-center, randomized, double-blinded, placebo-controlled, clinical trial.A total of 90 patients aged 20-45 years with endometriosis-associated pain were enrolled.Participants were randomly assigned to the proscur or placebo groups in a ratio of 1:1 and efficacy evaluation was conducted at day 30, 60 and 90.The participants orally administered proscur or placebo two times a day for 12 weeks.The study outcomes were measured based on a change of visual analogue scale (VAS) score and the short form endometriosis health profile questionnaire (EHP-5).Results: We observed an increase in pain relief in women who receive proscur.The serum measures of CA-125 declined in those who received proscur.Intervention was well tolerated, and no serious adverse events occurred.Conclusions: Our study showed that proscur relieved endometriosis-associated pain and CA-125 level with minimal side-effects after treatment.Therefore, proscur combined with standard medical therapy could provide more clinical benefits for patients with endometriosis-associated pain.

My notes (saved in your browser only)

Outcome instruments

EHP-30 VAS-pain

Condition tags

endometriosisdysmenorrheadyspareunia

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (48)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK